| Literature DB >> 35106418 |
Taichi Horino1, Ryuma Tokunaga1, Yuji Miyamoto1, Yukiharu Hiyoshi1, Takahiko Akiyama1, Nobuya Daitoku1, Yuki Sakamoto1, Naoya Yoshida1, Hideo Baba1.
Abstract
BACKGROUND: The advanced lung cancer inflammation index (ALI), which comprehensively evaluates the patient body composition and inflammation/nutritional status, is reportedly associated with the patient outcome in lung cancer. However, the clinical significance in colorectal cancer (CRC) patients after curative resection remains unclear.Entities:
Keywords: advanced lung cancer inflammation index; colorectal cancer; postoperative complication; recurrence; systemic inflammation
Year: 2021 PMID: 35106418 PMCID: PMC8786697 DOI: 10.1002/ags3.12499
Source DB: PubMed Journal: Ann Gastroenterol Surg ISSN: 2475-0328
FIGURE 1The preoperative ALI and long‐term patient outcome. (A) Flow chart for this study (inclusion/exclusion criteria). (B) Spline plots showing the HR for the overall survival and RFS using the preoperative ALI. (C) The probabilities (Kaplan–Meier plots) for the overall survival and recurrence rate. ALI, advanced lung cancer inflammation index; BMI, body mass index; HR, hazard ratio; NLR, neutrophil‐to‐lymphocyte ratio
Association between ALI and clinicopathological factors
| Characteristics |
Overall n = 813 |
ALI‐high n = 532 |
ALI‐low n = 281 |
|
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Sex | ||||
| Male | 464 (57%) | 219 (41%) | 245 (87%) | <.001 |
| Female | 349 (43%) | 313 (59%) | 36 (13%) | |
| Age | ||||
| <65 | 291 (36%) | 206 (39%) | 85 (30%) | .016 |
| ≥65 | 522 (64%) | 326 (61%) | 196 (70%) | |
| BMI (kg/m2) | ||||
| <18.5 | 95 (12%) | 54 (10%) | 41 (15%) | <.001 |
| 18.5≤, <25 | 536 (66%) | 328 (62%) | 208 (74%) | |
| ≥25 | 182 (22%) | 150 (28%) | 32 (11%) | |
| Tumor location | ||||
| Right side | 264 (32%) | 161 (30%) | 103 (37%) | .065 |
| Left side | 549 (68%) | 371 (70%) | 178 (63%) | |
| Depth of tumor invasion | ||||
| T1 | 198 (24%) | 154 (29%) | 44 (16%) | <.001 |
| T2 | 160 (20%) | 115 (22%) | 45 (16%) | |
| T3 | 342 (42%) | 205 (38%) | 137 (49%) | |
| T4 | 113 (14%) | 58 (11%) | 55 (19%) | |
| Lymph node metastasis | ||||
| Negative | 580 (71%) | 372 (70%) | 205 (73%) | .364 |
| Positive | 233 (29%) | 160 (30%) | 76 (27%) | |
| Stage | ||||
| I | 307 (38%) | 226 (43%) | 81 (29%) | <.001 |
| II | 274 (34%) | 149 (28%) | 125 (44%) | |
| III | 232 (28%) | 157 (29%) | 75 (27%) | |
| CEA (ng/mL) | ||||
| ≤5 | 590 (73%) | 412 (77%) | 178 (63%) | <.001 |
| >5 | 223 (27%) | 120 (23%) | 103 (37%) | |
| CA19‐9 (U/mL) | ||||
| ≤37 | 685 (84%) | 451 (85%) | 234 (83%) | .578 |
| >37 | 128 (16%) | 81 (15%) | 47 (17%) | |
Abbreviations: ALI, advanced lung cancer inflammation index; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen.
P value was based on the chi‐square test for categorical factors.
FIGURE 2The preoperative ALI and short‐term patient outcome. (A) The association between the preoperative ALI and postoperative complications. (B) The association between the preoperative ALI and severe postoperative complications (Clavien–Dindo classification ≥III). ALI, advanced lung cancer inflammation index
Association between ALI and patient survival outcome
| Clinicopathological factors |
Univariate HR (95% CI) |
|
Multivariate HR (95% CI) |
| |
|---|---|---|---|---|---|
| Overall survival | |||||
| Sex | Male/Female | 1.13 (0.79–1.61) | .496 | 0.75 (0.49–1.14) | .174 |
| Age | ≥65/<65 | 2.14 (1.45–3.25) | <.001 | 1.96 (1.32–3.00) | <.001 |
| Tumor location | Right side/left‐side | 1.41 (0.99–1.99) | .055 | 1.22 (0.85–1.74) | .286 |
| Depth of tumor invasion | T3‐T4/T1‐T2 | 1.59 (1.12–2.30) | .009 | 1.20 (0.82–1.77) | .346 |
| Lymph node metastasis | Positive/negative | 1.52 (1.06–2.17) | .024 | 1.47 (1.01–2.12) | .046 |
| Postoperative complication | CD classification ≥III/<III | 1.73 (1.12–2.58) | .015 | 1.57 (1.01–2.39) | .047 |
| ALI | Low/High | 2.27 (1.62–3.21) | <.001 | 2.30 (1.52–3.50) | <.001 |
| Relapse free survival | |||||
| Sex | Male/Female | 0.91 (0.69–1.20) | .496 | 0.69 (0.49–0.97) | .031 |
| Age | ≥65/<65 | 1.77 (1.30–2.45) | <.001 | 1.73 (1.27–2.41) | <.001 |
| Tumor location | Right side/left‐side | 1.09 (0.81–1.46) | .553 | 0.97 (0.71–1.31) | .846 |
| Depth of tumor invasion | T3‐T4/T1‐T2 | 2.47 (1.82–3.41) | <.001 | 1.86 (1.35–2.60) | <.001 |
| Lymph node metastasis | Positive/negative | 2.31 (1.74–3.05) | <.001 | 1.94 (1.45–2.60) | <.001 |
| Postoperative complication | CD classification ≥III/<III | 1.82 (1.28–2.52) | .001 | 1.64 (1.14–2.31) | .008 |
| ALI | Low/High | 1.70 (1.28–2.24) | <.001 | 1.73 (1.22–2.44) | .002 |
Abbreviations: ALI, advanced lung cancer inflammation index; CD classification, Clavien–Dindo classification; CI, confidence interval; HR, hazard ratio.
Multivariate Cox proportional hazards regression model was adjusted for sex, age, tumor location, depth of tumor invasion, lymph node metastasis, postoperative complication, and ALI status/PNI.
FIGURE 3Results of a subgroup analysis according to the ALI for the long‐term patient outcome. ALI, advanced lung cancer inflammation index